- Home
- PTC vs EXEL Comparison
PTC vs EXEL Comparison
Compare PTC & EXEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | PTC | EXEL |
|---|---|---|
| Founded | 1985 | 1994 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 13.4B | 14.0B |
| IPO Year | 1995 | 2000 |
Fundamental Metrics
Financial Performance| Metric | PTC | EXEL |
|---|---|---|
| Price | $124.91 | $55.74 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 11 | 21 |
| Target Price | ★ $183.09 | $46.50 |
| AVG Volume (30 Days) | 2.1M | ★ 2.5M |
| Earning Date | 05-06-2026 | 05-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 94.87 | 57.95 |
| EPS | ★ 6.35 | 0.79 |
| Revenue | ★ $2,739,226,000.00 | $452,477,000.00 |
| Revenue This Year | $0.03 | $13.61 |
| Revenue Next Year | $6.20 | $13.13 |
| P/E Ratio | ★ $19.65 | $71.53 |
| Revenue Growth | ★ 19.18 | N/A |
| 52 Week Low | $108.50 | $33.76 |
| 52 Week High | $219.69 | $57.57 |
Technical Indicators
Market Signals| Indicator | PTC | EXEL |
|---|---|---|
| Relative Strength Index (RSI) | 51.54 | 59.82 |
| Support Level | $109.84 | $40.77 |
| Resistance Level | $148.74 | N/A |
| Average True Range (ATR) | 3.95 | 1.54 |
| MACD | 1.85 | 0.09 |
| Stochastic Oscillator | 83.36 | 73.99 |
Price Performance
Historical ComparisonAbout PTC PTC Inc.
PTC is a US-based global company that offers high-end computer-assisted design, product lifecycle management, and augmented reality solutions that industrial manufacturers commonly use on factory floors. Founded in 1985, PTC is a major player in parametric design and serves some of the world's most well-known equipment manufacturers, such as Caterpillar, Garmin, and Thermo Fisher.
About EXEL Exelixis Inc.
Exelixis Inc is a biopharmaceutical firm that discovers, develops, and commercializes treatments for cancer. Its molecule, cabozantinib, is indicated for the treatment of patients with metastatic medullary thyroid cancer under the name Cometriq and for the treatment of kidney and liver cancer under the name Cabometyx. Exelixis and its partner Roche have also brought Cotellic to market for the treatment of melanoma.